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Members of the evolutionarily conserved family of the chicken ovalbumin upstream promoter transcription factor NR2F/
COUP-TF orphan receptors have been implicated in lymphocyte biology, ranging from activation to differentiation and
elicitation of immune effector functions. In particular, a CD4+ T cell intrinsic and non-redundant function of NR2F6 as a
potent and selective repressor of the transcription of the pro-inflammatory cytokines interleukin (Il) 2, interferon y (ifng)
and consequently of T helper (Th)17 CD4+ T cell-mediated autoimmune disorders has been discovered. NR2F6 serves as
an antigen receptor signaling threshold-regulated barrier against autoimmunity where NR2F6 is part of a negative
feedback loop that limits inflammatory tissue damage induced by weakly immunogenic antigens such as
self-antigens. Under such low affinity antigen receptor stimulation, NR2F6 appears as a prototypical repressor that
functions to “lock out” harmful Th17 lineage effector transcription. Mechanistically, only sustained high affinity antigen
receptor-induced protein kinase C (PKC)-mediated phosphorylation has been shown to inactivate NR2F6, thereby
displacing pre-bound NR2F6 from the DNA and, subsequently, allowing for robust NFAT/AP-1- and RORγt-mediated
cytokine transcription. The NR2F6 target gene repertoire thus identifies a general anti-inflammatory gatekeeper role for
this orphan receptor. Investigating these signaling pathway(s) will enable a greater knowledge of the genetic, immune,
and environmental mechanisms that lead to chronic inflammation and of certain autoimmune disorders in a given
individual.
Keywords: Autoimmune disease, Pro-inflammatory Th17 cells, Nuclear orphan receptors, Immune response balance and
check, NR2F-orphan receptor family, NFAT, AP-1, RORγt, Transcriptional regulationLay abstract
Recent research defines nuclear orphan receptor NR2F6 as
a critical gatekeeper for Th17-dependent immune effector
responses in mouse T cells. Importantly, the ligand binding
domain of NR2F6 is evolutionary highly conserved and has
been shown by us to be essential for its transcriptional re-
pressor activity, validating NR2F6 as particular druggable
target for immune modulation. Thus, this newly defined
concept is providing a rational mechanistic basis for a se-
lective agonist of NR2F6 to attenuate the pro-inflammatory
cytokines IL-17A, IL-17F, IL-21 and IFNγ production in
Th17 cell-mediated immune pathologies. Targeted manipu-
lation of this Th17-subtype selective NR2F6 function may
represent a unique therapeutic option to selectively sup-
press and/or reprogram pathological Th17 cell in i.e. mul-
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The immune system protects our bodies against invasion
by pathogens of viral, bacterial, fungal and parasitic ori-
gin and against growth of neoplastic cells. The intensity
of the adaptive immune responses must be tightly regu-
lated in terms of class and duration to allow the proper
production of immunoregulatory cytokines or chemo-
kines by T lymphocyte subsets and the differentiation of
B cells that are able to produce various antibody classes.
Subsequently, the interaction between innate and adap-
tive immune cells provides the best protection for the
organism while preventing, as far as possible, collateral
damage to bystander tissue. However, because it is a
tightrope-walk situation, this delicate balance can be
subverted by severe infections, disruption of tissue integ-
rity or genetic susceptibility. Under such conditions,
acute immunological pathology such as persistent infec-
tion, chronic inflammatory disease and/or autoimmunity
may occur.oMed Central Ltd. This is an Open Access article distributed under the terms of
tp://creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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http://www.biosignaling.com/content/12/1/38To be able to modulate such immune diseases clinically,
it is essential to both fully understand the positive and
negative pathways that regulate immune homeostasis and
to predict the adverse effects that could occur during host
protection. It is well recognized that such immune cell sig-
naling networks are strongly influenced by an array of dis-
tinct nuclear receptors (NRs). In humans the NR super
family consists of 48 transcription factors from the steroid
hormone, thyroid hormone, oxysterol as well as lipid recep-
tors. In the immune system, NRs are involved in diverse
processes such as development, activation, apoptosis, subset
differentiation and homeostasis regulation. It is becoming
increasingly clear that immune response outputs are or-
chestrated by both the expression level and the transcrip-
tional activity of several members of the NR family
including the glucocorticoid (GR/NR3C1), estrogen (ER/
NR3A1&2), vitamin-D3 (VDR3/NR1I1), nuclear receptor
subfamily 4, group A, member 2 (NR4A2), peroxisome
proliferator-activated receptor γ (PPARγ/NR1C3) or the
retinoic acid receptors (RAR/NR1B1). Specifically, these
NRs appear to allow a fine tuning of immune cellular pro-
cesses to environmental changes such as external milieu
signals and the cell intrinsic metabolic state during host
protection [1-4]. Notably, NRs have been shown to be es-
sential for both the pro-and anti-inflammatory processes in
health and disease. Consistently, in both mice and humans,
NR mutations have been specifically associated with im-
mune deficiencies or autoimmunity [3,5-9].
The nuclear orphan receptors of the chicken ovalbu-
min upstream promoter transcription factor (COUP-
TF)/NR2F-family are proteins that are involved in a wide
range of physiological processes. The NR2F-family con-
sists of three orphan receptors, which are named
NR2F1, NR2F2 and NR2F6 in accordance with the Nu-
clear Receptors Nomenclature Committee (Table 1), and
which are central to distinct aspects of metazoan physi-
ology. The NR2F-family members regulate processes as
diverse as embryonic and neuronal development, cancer
or metabolism.
Review
Functional domains and transcriptional targets of
NR2F-family members
The family tree and protein domain structure of the NR2F-
family that are shown in Figure 1 has been described in
detail [10-12]. NR2F-family members homodimerize orTable 1 Nomenclature of mammalian NR2F-family members and
NR2F1 N
ERBA-related protein Ear3 Apolipoprotein reg
COUP transcription factor I or 2, COUP-TF I or 2 COUP transcription
COUP-TFII, Tc
V-erbA-related protein 3; avian erythroblastic leukemia
viral (v-erb-a) oncogene homolog-like 3; Erbal3
ADP-ribosylation factoheterodimerize with retinoid X receptor (RXR/NR2B1) as
well as other nuclear receptors and bind to a variety of re-
sponse elements that contain imperfect AGGTCA direct or
inverted repeats with various spacing on the cognate DNA
sequence [13-15]. Although such specific sequences have
been described to be preferentially recognized by NR2F-
family members, the promoter site-intrinsic features
through which distinct NR2F responsive enhancers encode
positive versus negative transcriptional outcomes remains
unresolved.
Physiological roles of NR2F1 and NR2F2 in non-
hematopoietic cells have been reviewed in detail lately
and have been identified to be critical regulators in cell
differentiation, tissue development, angiogenesis and
metabolism [16,17]. The family member NR2F6 was not
reviewed by Tsai [12,18,16] although it has been thought
to be functionally closely related [15]. However, and un-
like Nr2f1 and Nr2f2 knockout mice, Nr2f6-deficient
mice are viable and fertile, and they have an underdevel-
oped locus coeruleus of the forebrain, which causes de-
fects in nociception and in circadian clock behavior [19].
Despite its function in the central nervous system
NR2F6 is also suggested to repress mouse renin, human
oxytocin or rat LH gene transcription [20-24]. Additionally,
NR2F6 has been found to be strongly over-expressed in
colorectal cancer and to regulate the survival of tumor
cells [25].
Physiological roles of NR2F1, NR2F2 and NR2F6 in
hematopoietic cells
The expression of Nr2f1 and Nr2f2 in distinct subpopula-
tions of immune cells has been analyzed [26]. Nr2f1 and
Nr2f2 family members are expressed in human CD4+,
CD8+, CD19+, and CD14+ cells. In addition the expression
pattern of the Nr2f gene family has been investigated in
resting and activated T, B, NK, and dendritic cells by the
ImmGen Consortium (http://www.immgen.org). All Nr2f
family members are expressed in diverse adaptive and in-
nate immune cells. Of note, and as a general rule of thumb,
the mRNA expression levels of Nr2f6 in hematopoietic cells
are increased approximately twofold in comparison to the
mRNA expression levels of Nr2f1 and Nr2f2 [27]. Although
these Nr2f-family members have been investigated exten-
sively in non-hematopoietic cells, little is known about their
critical role in the immune compartment [2,28,29], and as
reviewed in [16,18,30]. Possibly this is because Nr2f1 andtheir synonyms (according to http://www.ncbi.nlm.nih.gov)
R2F2 NR2F6
ulatory protein 1, ARP1 V-erbA-related protein 2; Ear2
factor II or 2, COUP-TF2,
fcoup2, COUPTFB
COUP transcription factor 3, COUP-TF3
r related protein 1, Aporp1 Avian erythroblastic leukemia viral (v-erb-a)
oncogene homolog-like 2, Erbal2
Gene Family
 1 83 162 179  422
 1 75 155 172  414
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Figure 1 Schematic protein domain structure of NR2F-family members. (A) Nuclear receptor gene family and its phylogenetic tree (source:
nuclear receptor resource; John P. Vanden Heuvel, http://nrresource.org) (B) The common domain structures of NR2F1, NR2F2 and NR2F6 from
the amino- to the carboxyl-terminus are indicated: the amino-terminal activation function 1 (AF1) domain (also called the A/B region), the central,
highly conserved, DNA-binding-domain (DBD) (also called the C region), the hinge region (also called the D region), the ligand-binding domain
(LBD) (also called the E region) and the activation function 2 (AF2) domain (also called the F region) and their relative positions. Briefly, the DNA
binding domain (DBD), also called C region, of the different mammalian NR2F-family members is highly homologous between different species,
which indicated the importance of this critical region for the biological function of these proteins [18]. The A/B region, which is highly variable
among different nuclear receptors, is located amino-terminal to the DBD domain. In general, this domain may contain ligand-independent
transcriptional activity. The second most conserved region is the ligand binding domain (LBD) or E region, which is responsible for recognition
and binding of the receptor’s ligand and for the ligand-dependent transcriptional activity. A relatively short region connects the C region to the E
region (region D) and is also known as the hinge domain. Some receptors also contain a region that is carboxy-terminal to the ligand binding
domain, which is known as the F region [1,13,18,97].
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http://www.biosignaling.com/content/12/1/38Nr2f2 deficiencies in mice are fatal and only conditional
knockout mice are available for analysis: Owing to the rela-
tively low levels of Nr2f1 and Nr2f2 transcripts in restinglymphocytes [27,31-33], when compared to, e.g., ovary, kid-
ney or brain, such conditional knockouts for the immune
compartment have not yet been generated.
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that NR2F-family members are powerful regulators of
immune cell activation and that expression of this pro-
tein family must be tightly controlled in lymphocytes.
Because of this possibility and because, dependent upon
the microenvironment, memory/effector T cells change
expression profiles with their effector differentiation into
a specialized subset, it remains a worthy goal to investi-
gate the potential immune system roles of all NR2F-
family members in more detail. In fact, signaling path-
ways that are known to be regulated by NR2F-family
members in non-hematopoietic tissues, such as the
RAR, TR, VDR, PPARγ, the arylhydrocarbon receptor
(AhR), the forkhead box sub-group O (Foxo3a) and the
hepatocyte nuclear factor 4 (HNF4/NR2A4) are well
known to be critical also in adaptive immune responses
[10,12,17,34-38]. NR2F2 generally is thought to func-
tionally interact with many different signaling pathways
such as Notch, β-catenin, transforming growth factor-β
(TGFβ), HNF4α, runt related transcription factor (Runx)
2, PPARγ, CCAAT/enhancer binding protein (C/EBP) α,
GATA, RARα or PPARα pathways [34,39-48]. Albeit that
all these are known to be highly relevant in inflamma-
tory and/or immune responses, a potential relevance of
NR2F2 in specific immune cell subsets has not yet been
investigated.
Nevertheless, several studies may indeed indicate a role
for all three NR2F-family members in human immune
function and in lymphomas and leukemia. Augmented
NR2F1 expression has been identified in the pre-disease
state of multiple sclerosis patients, potentially indicating a
role in the development of autoimmune disease [49]. In the
rare autosomal recessive immune disorder, called ICF syn-
drome (or Immunodeficiency, Centromere instability and
Facial anomalies syndrome) microarray experiments and
real-time RT-PCR assays revealed significant differences in
RNA levels for NR2F2 in lymphoblasts from ICF patients
[50]. In humans NR2F2 is strongly upregulated in CD4+
and CD8+ T cell lymphoma cells, while NR2F6 expression
has been shown to be upregulated in lymph nodes [51]. In
addition, NR2F6 is significantly upregulated in Anaplastic
Large Cell lymphoma compared with Hodgkin lymphoma
in human patients [52]. Finally, NR2F6 is deregulated in
CD4+ T cells of adult T cell leukemia patients [53]. In pre-
clinical leukemia models, NR2F6 has been suggested to
regulate the maintenance of the clonogenic status within
the cell hierarchy of the cancer cells [54]. While Nr2f6 is
highly expressed in hematopoietic stem cells, its expression
declines strongly upon normal hematopoietic differenti-
ation as well as the transitions of KSL (c-kit+, sca-1+,
lineage−) hematopoietic stem cell to an immature double
negative (DN1) T cell stage and from DP to the CD8+ SP
cells. Of note, Ichim et al., describes a candidate regulatory
role of NR2F6 during T cell development. Bone marrowreconstitution experiments with forced overexpression of
recombinant NR2F6 resulted in limited T cell development
and decrease in thymus size and cellularity [55]. Addition-
ally, NR2F6 expression has also been found to be signifi-
cantly downregulated in CD19+ B cells of systemic lupus
erythematosus patients [56].
NR2F6 appears to restrain Th17-dependent autoimmunity
In addition to its established role in the brain, recent
data define NR2F6 as a critical regulatory factor in the
adaptive immune system [57] and one of its key func-
tions appears the repression of cytokine production in T
cells. The ability of NR2F6 to reversibly suppress the
transcription of the TCR/CD28-transactivated transcrip-
tion factors such as the nuclear factor of activated T cells
(NFAT) and the activating protein 1 (AP-1) mechanistic-
ally explains its ability to limit IL-2 and IFNγ produc-
tion. Consistent with this observation, it is well
documented that several other NRs, such as the steroid
receptors, PPAR, RXR, RAR, and VDR repress the ability
of NFAT and/or AP-1 to transcribe their target genes in
T cells and this interference is the established basis for
the anti-inflammatory actions of corticosteroids [58-63].
Examination of Nr2f6 expression revealed that Nr2f6
mRNA is upregulated in a subset of CD4+ T cells that
are commonly known as T helper 17 CD4+ (Th17) cells
[57]. Indeed, in the experimental autoimmune enceph-
alomyelitis (EAE) model, a significantly augmented dis-
ease progression of Nr2f6 knockout mice establishes a
critical and non-redundant functional threshold mech-
anism of NR2F6 for repressing Th17 cell pathology both
in vivo and in vitro [57]. When biochemically investigat-
ing the immune cell intrinsic NR2F6 signaling function(s),
NR2F6 appears to counteract the calcium/calcineurin/
NFAT-signaling pathway. Mechanistically, NR2F6 directly
binds to multiple sites within the Il17a promoter locus and
suppresses the DNA accessibility of endogenous NFAT
in resting or suboptimally stimulated Th17 cells. In
fact, an antagonistic association between NFAT and
NR2F6 occupancy on common target genes in T cells
strongly suggests a competitive interaction between
these TFs. Indeed, NFAT was coimmunoprecipitated
with NR2F6 in a DNA scaffold dependent manner,
which indicates that these two TFs form a heterodi-
meric protein:protein complex when bound on DNA.
This may either suggest a direct physical competition
for high-affinity binding sites and/or subsequently, a
transcriptional repression of NFAT by NR2F6. Consist-
ent with this notion, both the physical protein:protein
interaction with NFAT and the trans-repression mode
of NR2F6 is critically dependent on the DNA-binding
and the ligand-binding domains of NR2F6, at least
when investigated upon coexpression of recombinant
TFs in a T cell line [64].
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Th17 lineage nuclear orphan receptor RORγt for the
DNA accessibility to the hormone response elements
within the Il17a conserved noncoding sequences (CNS)2
promoter region (Figure 2) [64,65]. Similar to NR2F6,
the nuclear receptors RAR, PPAR, LXR, VDR, GR and
ER repress Th17 differentiation and protect against the
EAE disease mouse model. Nevertheless, the lineage spe-
cific TFs that positively induce the differentiation of
Th17 cells are RORγt and RORα [66-75]. This opposite
behavior of i.e. RORγt might be explained by its DNA
binding capability as a monomer whereas all the other
NRs (that restrain Th17 cell functions) are described by
their DNA binding capabilities as dimers, both as homo-
or heterodimers [76,77].
Thus and although these few defined lineage TFs or-
chestrate synexpression gene clusters that serve in dis-
tinct pathways, lineage specificity and plasticity remains
a product of the complex combinatorial regulation of
gene transcription. Analogous to other pluripotent pro-
genitor cells, particularly naïve CD4+ T cells face the
challenge of balancing stability and plasticity in their
gene expression programs as they differentiate into their
highly specialized subsets under the influence of their
microenvironment. Recent studies, have generated such
a detailed insights into the complexity of T cell lineage
differentiation programs especially for the Th17 lineage
that appears to be controlled and limited by positive and
negative feedback circuits [78,79]. Transcription initi-
ation at sites that are occluded by nucleosomes and
high-order chromatin structure is established to require
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Figure 2 The Il17a promoter and its regulation by orphan nuclear recept
sequences (CNS) are controlled by the general transcriptional machinery and by
the minimal and the CNS2 region of the Il17a promoter for NFAT and for nucle
receptors, RORγt and NR2F6, thereby have key roles in Il17a gene regulation. Of
with co-binding partners that are either co-activators or co-repressors. These co
inhibit or stimulate target gene transcription. NR2F6 thereby plays a fundament
and inflammation, as do several other nuclear receptors such as the AHR, RARs,
RORγt is the only nuclear receptor established to enhance Th17 differentiation aappropriate regulators [80]. Consistently, chromatin ac-
cessibility analysis suggests that such TF complexes pi-
oneer the access of additional TFs and, subsequently,
further specify functional subset programming. In the
presence of Th17-polarizing cytokines, STAT3, NR2F6
and RORγt are likely to be recruited to many of the
same promoters. Intriguingly however, NR2F6 occu-
pancy appears to also strongly overlap with that of
NFAT. A long this line of argumentation, such an epi-
genetic chromatin remodeling role, especially for
NFAT2, in transcriptional regulation has been suggested:
Because NFAT2 is strongly upregulated in Th0 cells, it
has been speculated that the NFAT-mediated pioneering
function provides the T cell with plasticity to differenti-
ate in multiple directions, depending on the cytokine en-
vironment [81]. Thus, whereas Th17 signals recruit
signal-transducer and activator of transcription protein
(STAT)3/RORγt to a subset of NFAT/AP-1 binding sites,
Th1 or Th2 signals recruit STAT1/T-bet or STAT6/
GATA-3 to other NFAT/AP-1 binding sites. Of note, es-
pecially Th17 cells are sensitive to low NFAT levels [82],
albeit NFAT and AP-1 have also roles in other Th sub-
sets [83]. Consistently, NR2F6 may serve as an inte-
grated regulator of the defined Th17 helper cell lineage
identity and/or plasticity that functions by repressing
transcriptional programs at key gene loci.
Importantly, and in contrast to other NRs, constitu-
tively lymphocyte-expressed NR2F6 is already prebound
to its hormone response elements within i.e. the Il17a
cytokine promoter loci in a resting state and thereby
may simply inhibit the induced DNA binding capacities








ors. The interleukin (Il) 17a minimal promoter and conserved non-coding
several nuclear receptors. The DNA consensus binding sequences within
ar receptors such as NR2F6 and RORγt are shown. Two orphan nuclear
note, NR2F-family members form homo- or hetero-dimers that interact
mplexes bind to their consensus sequences (HRE) in the DNA to either
al role in the CD4+ T cell compartment by balancing Th17 differentiation
PPARs, LXR, VDR, GR and ER. The lineage-specific master transcription factor
nd restrains iTregs.
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http://www.biosignaling.com/content/12/1/38cartoon in Figure 3). The current experimental evidence
thus might suggest that NR2F6 similarly affects re-
sponses by remodeling the chromatin landscape, which
would critically control the subsequent recruitment of
other TFs involved in regulating the expression of adja-
cent genes. Next to IL-17, Nr2f6-deficient T cells also re-
press IL-2 and IFNγ, which indicate that NR2F6 may
serve as a more general gatekeeper by directly preoccu-
pying binding sites for NFAT to prevent transcriptional
activation [57]. This conveys an important message for
Th17 subset selectivity and indicates that NR2F6 specif-
ically counteracts the generation of the highly patho-
genic Th17 cell type and decreases the risk of promoting
autoimmunity [57]. Intriguingly and of note, NR2F6
however appears to alter the transcription levels of only
a selected subset of genes rather than promote large-
scale changes in gene expression. The exact mode of ac-
tion of NR2F6 function, however, remains further de-
tailed investigations. In contrast to Th17 cells, NR2F6
appears dispensable, or at least less critical, for Th1 and
Th2 functions. This renders NR2F6 an exceptional drug
target because therapeutic intervention would not be ex-
pected to perturb the generic regulatory programs that
are shared by other immune cell types. In this context, it
will be necessary to compare the global distributions of
NR2F6 and NFAT and of lineage-specifying TFs in Th17,
iTreg, Th1 and Th2 cells. NR2F6 might thereby appear
as a prototypical repressor candidate that functions to






















Figure 3 Nuclear receptor NR2F6, as a signal-induced functional switch, t
of signaling events in Th17 cells is shown: NR2F6 serves as a TCR/CD28 signalin
a negative feedback loop that limits inflammatory tissue damage. In the absenc
response element (RE) and recruits co-repressors to suppress transcription of de
is phosphorylated by PKC and, thereby, loses its DNA binding capacity; subsequ
sequences and recruit additional co-activators to activate transcription of, e.g., Il1
sites throughout the genome. Thus and intriguingly, NR2F6 emerges as a proto
stimulation, “locks out” Th17 lineage programming. Because Th17 cell-intrinsic fu
cytokine transcription, NR2F6 agonists may provide a rational basis for the treatmNR2F6 is itself regulated
Nr2f6 mRNA
Because CD4+ T lymphocytes can differentiate into several
diverse subsets depending on microenvironmental milieu
factors and similarly to the FOXO transcription factor fam-
ily, expression of the NR2F-family might influences cellular
potential [84]. We showed that the expression of NR2F6
was regulated upon TCR/CD28 stimulation and cytokines
in the Th17 polarization milieu strongly increased Nr2f6
expression in T cells [57]. Thus, transcriptional regulators
of the Nr2f6 locus, albeit currently undefined, appear to be
induced in response to Th17-polarizing conditions. In silico
analysis strongly indicates, that the Nr2f6 promoter may
have functional STATand NR sites [85].Post-translational modification (PTM) of NR2F6
Antigen receptor-induced protein kinase (PK)C-medi-
ated phosphorylation has been shown to inactivate
NR2F6, thereby allowing for robust cytokine responses
[57]. Mechanistically, Ser-83, which is located within the
DBD of NR2F6, appears to be the main phosphorylation
site upon TCR stimulation to abrogate the DNA-binding
capacities of NR2F6 and subsequently allows NFAT/AP-
1 binding at the given promoters. Thus, only phosphor-
ylation of NR2F6, which is mediated by a sustained PKC
activity downstream of full and robust TCR/CD28 acti-
vation, promotes unopposed NFAT and/or RORγt-
mediated DNA binding at the critical cytokine gene loci

















hat safeguards Th17 cell effector functions. A schematic representation
g threshold regulated barrier against autoimmunity where NR2F6 is part of
e of a strong antigenic signal, NR2F6 remains pre-bound to the signal
fined gene loci. In high-affinity antigen-stimulated T cells, however, NR2F6
ently, NFAT and/or RORγt are able to bind to their promoter/enhancer
7a. In robustly activated CD4+ T cells, NFAT and AP-1 bind cooperatively to
typical repressor that, in the absence of high affinity antigen receptor
nction of NR2F6 renders Th17 cells less pathogenic by repressing key
ent of Th17-mediated autoimmune pathologies.
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the ER (NR3A), RAR (NR1B), PPARs (NR1C), LXR
(NR1H3) VDR (NR1I1), and GR (NR3C1) [61,86-90],
whereas AhR activates the Il2 promoter [91]. Similarly
to NR2F6, the DNA binding domains of other nuclear
receptors, such as Nur77 (NR4A1), RARα (NR1B1), ERα
(NR3A1), or the VDR (NR1I1), are directly phosphory-
lated by PKC or PKA as reviewed previously [92,93]. A
significant difference between the formerly mentioned
NRs and NR2F6 is the constitutive presence of NR2F6 at
its hormone response element (HRE) of the DNA in
resting cells, whereas the other NRs are activated via en-
vironmental stimuli and subsequently adapt the cell to
the microenvironment through their DNA binding cap-
ability. Additionally, the number and diversity of other
PTM covalent modifications of NR2F6, such as acetyl-
ation, ubiquitination or sumoylation which are well
known to shape nuclear receptor activity [9,94], have
just begun to be analyzed.
NR2F6-Ligand?
Although the NR2F-family remains defined as orphan
NRs, a significant interest in the identification of the de-
tailed molecular mechanisms and identification of en-
dogenous ligands that may regulate these NRs exists. Of
note, a recent study has shown that NR2F2 is a retinoic
acid-activated receptor [95]. This ligand-regulated fea-
ture of NR2F2 (albeit retinoic acid has a rather low affin-
ity) has left open the possibility that, although currently
undefined, endogenous NR2F-family specific ligands
may exist as agonists or antagonists and may modulate
the functions of NR2F-family members. In this regard,
the findings that high levels of retinoic acid trigger iTreg
formation might be relevant [95]. Detailed studies are
now urgently needed to determine the physiological con-
sequences of mRNA regulation, covalent PTM modifica-
tions, and the existence of modulatory function(s) of
endogenous ligands of NR2F6 function in detail.
NR2F6 as a drug target in molecular medicine
Environmental factors and gender undoubtedly play key
roles in the susceptibility to autoimmune diseases, but
clearly genetic disposition is also important. These
NR2F6–mediated transrepression is proposed to have
roles in controlling both the initiation, magnitude and
duration of pro-inflammatory gene expression, and, thus,
in targeting NR2F6-specific mechanisms, both local and
systemic inflammation appear amenable to clinical ma-
nipulation. NR2F6 could potentially represent such a
genetic risk factor for the development of autoimmune
diseases through its regulation of pathogenic Th17 cells.
In deed, NR2F6 has been identified as a type 1 diabetes
susceptible SNP (http://arxiv.org/pdf/1404.4482.pdf) and
as a risk allele in autoimmune leukocytes [96]. It nowwill be interesting to further validate this potential gen-
etic association of allelic NR2F-family variants/SNPs
with health and disease.
Of note, nuclear receptors have been a rich source of
drug targets, especially for inflammation-mediated dis-
eases but also in lipid, carbohydrate and energy homeo-
stasis [32]. Over the past few years, significant
breakthroughs in the identification of ligands both from
natural as and from synthetic sources have occurred, as
reviewed by Burris [97]. The newly defined repressor,
NR2F6, may be a compelling and well-validated new tar-
get for regulating the Th17 lineage balance and for
switching pathogenic Th17 into non-pathogenic cells.
Furthermore, the effect would be largely specific for
Th17 cells because we did observe comparable effector
response outcomes during the differentiation of the
other CD4+ T cell subset. In addition, the lack of main-
tenance function of NR2F6 in adult organs renders it a
potentially safe target for the treatment of immune
diseases.
Taken together, this NR2F6-centered pathway identified
may very well offer new targets that are aimed at blocking
the generation of pathogenic Th17 cells for the treatment
of autoimmune diseases. Although our current preclinical
knowledge strengthens this hypothesis, the direct causality
of NR2F6 and incidence of human autoimmune disease re-
mains yet to be demonstrated (Table 2).
Conclusions
Here, we describe recent studies that extend our under-
standing of how the NR2F-family member NR2F6 exerts
important regulatory roles in adaptive immunity. In our
model, NR2F6 exerts its Th17-negative regulatory func-
tion as a transcriptional repressor that competes with
Th17-positive transcription factors over binding sites,
which is analogous to the action of other NRs. Import-
antly, however, NR2F6 appears to alter the transcription
levels of only a very selected subset of genes rather than
promoting large-scale changes in gene expression. Of
note, NR2F6 may act differently on various promoters to
modulate transcription, and its effect may be dependent
upon epigentics or possibly concurrent direct and indir-
ect interactions between other proteins and NR2F6.
NR2F6 might also share functions with its paralogs
NR2F1 and NR2F2 in the repression of key cytokine
mRNAs that control Th17 cells and systemic inflamma-
tion. Studies that include genome-wide approaches and
detailed analyses of NR2F-family-dependent genetic pro-
grams will be essential to comprehensively understand
the relationship between NR2F-family activity and dis-
tinct human diseases.
Nevertheless, our current functional model provides
an excellent starting point for deciphering the under-
lying physical interactions with DNA binding profiles or
Table 2 Physiological functions of NR2F family members and their roles in disease
NR2F1 NR2F2 NR2F6
Immune system Autoimmunity, expressed
CD4+/CD8+ and CD19+ cells [26,49]
Autoimmunity, expressed CD4+/CD8+
and CD19+ cells [26,50,51]
T cell development, activation thresholds,
CD4+ Th17 autoimmunity, leukemia [51,53,54,57,64,98]
T cells [27], http://www.immgen.org + + +++
B cells [27], http://www.immgen.org + + +++
Development Embryo, eye, hair, ear, angiogenesis [99] ES cell differentiation, mesenchyme, angiogenesis,
vessel identity, cerebellum, lymphangiogenesis,
stomach, eye, osteoblast [34,100-102]
Hormone regulation LHβ, Vegf, LH, receptor, RAR [103] LH receptor, oxytocin [22-24,104]
Cancer Breast & prostate cancer, MC-lymphoma,
metastasis, AML [43,105]
Colorectal, survival [25,52,54,106]
Metabolism Lipid uptake [41,103] Insulin secretion, adipogenesis, energy
metabolism
Lipid metabolism [107,108]
CNS Axons formation [109] Circadian rhythm, nociception [19,110-112]
Cortex patterning
Fate specification
Kidney Renin production Renin production [20,21,113]
Reproduction Reproduction
The expression pattern of the Nr2f gene family has been investigated in resting and activated T and B cells by the ImmGen Consortium (http://www.immgen.org). All Nr2f family members are expressed in diverse
adaptive and innate immune cells. Of note, and as a general rule of thumb, the mRNA expression levels of Nr2f6 in hematopoietic cells are increased approximately twofold in comparison to the mRNA expression
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http://www.biosignaling.com/content/12/1/38protein–protein interactions. Specifically, mechanistic
studies will be able to determine the physiological conse-
quences of transcriptional regulation and the covalent
modifications of NR2F6 in detail. Because nuclear recep-
tors are well-established drug targets, pharmacological
modulation of NR2F6 may represent an innovative
therapeutic regimen for counteracting the pathogenic
phenotype of Th17 cells.
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cell death; AP-1, activating protein-1; Bcl6, B-cell lymph-
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ing protein; ChIP, chromatin immunoprecipitation; CNS,
conserved noncoding sequences; Clock, circadian locomo-
ter output cycles kaput; DBD, DNA binding domain; EAE,
experimental autoimmune encephalomyelitis; ER/NR3A,
estrogen receptor; Foxo3a, the forkhead box sub-group O;
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